Home Blog

Zesty Paws to be acquired by H&H Group

0

Acquisition is a strategic opportunity for H&H as the company builds its Pet Nutrition & Care (PNC) division as a third pillar alongside its existing business segments – Adult Nutrition & Care (ANC) and Baby Nutrition & Care (BNC). Recognizing the importance and role that pets play in the lives of modern families around the world, Zesty Paws aligns with H&H’s mission to make people and pets healthier and happier.

“We are delighted to be working with H&H Group to further realize Zesty Paws’ vision to be recognized as the global leader in dog and cat health and wellness,” said Steve ball, CEO of Zesty Paws. “This acquisition combines the H&H Group’s mission of health and happiness for all, with our passion for holistic pet health, to create a greater opportunity for Zesty Paws to bring transformative supplementation to pets in the world. whole world.”

“The companion animal supplementation market has shown great resilience and accelerated growth, and we believe Zesty Paws is well positioned to make a strong contribution to the H&H Group offering,” said Laetitia Garnier, CEO of the H&H group. “Zesty Paws has established a strong brand and a premium line of high quality dog ​​and cat supplements, with a pioneering spirit of innovation at the core. The combination of the attributes of Zesty Paws and the brand’s reputation in the market American premium supplements for companion animals, and the growing demand for quality animal nutrition on a global scale makes this a very interesting opportunity for our Group. ”

Based at Orlando florida, Zesty Paws was founded in 2015 with a mission to enable and inspire a zest for life in pets and pet parents. Driven by his innovative spirit, Zesty Paws has launched a line of pet supplements to support many ailments common to dogs and cats, with highly effective formulations using branded ingredients. With an unprecedented number of five-star ratings and reviews (over 200,000 at May 2021), Zesty Paws is currently the # 1 selling multi-condition pet supplement brand in the US, with a CAGR of 62% + over the past 2 years. The brand has been successful in e-commerce channels like Amazon.com and Chewy.com, and has successfully grown into retail through pet specialty PetSmart and mass distribution Target. Since launch, Zesty Paws has continued to disrupt the pet supplementation space with gentle chews, liquids, meat squares and oral health sticks in different conditions such as skin. and coat, immune support, multifunctional, gut health, behavior and hip. & Cut.

About Prickly Paws:

Since 2015, Paws prickly® is led by a team of pet parents who are committed to providing premium products to enable and inspire a ZEST FOR LIFE in pets and pet parents. As the top rated pet functional supplement brand, Zesty Paws® is the most trusted brand for innovative solutions that guide and strengthen the path to well-being. Specialized in dog and cat care, Zesty Paws® Keep Your Bestie Feeling Zesty products. For more information visit https://zestypaws.com/.

About the H&H Group:

H&H Group is a dynamic, courageous and ambitious global health and nutrition company in its desire to inspire well-being, while making a positive contribution to the needs of society and the planet. The Group has three business segments – Nutrition and Care for Babies, Adults and Pets – supporting the health and happiness of the whole family, with premium brands providing nutrition and wellness solutions supported by Science. Consumer brands include Swisse, Biostime, Solid Gold Pet, Dodie, Good Goût, Aurelia Probiotic Skincare and CBII.

The Group manages the Biostime Institute for Nutrition and Care, and has research and development centers in Europe, China and Australia. Its business innovation arm NewH2 invests in emerging global technologies in health, nutrition and wellness.

H&H Group is headquartered in Hong Kong SAR and is listed on the Hong Kong Stock Exchange (stock code “H&H INTL HLDG” 1112), with over 3,000 teams operating in 14 countries – Australia, New Zealand, Greater China, India, Singapore, Malaysia, Thailand, France, Italy, Switzerland, the Netherlands, Ireland, England, and United States

The Group is part of the largest global corporate social responsibility initiative, the United Nations Global Compact, and is committed to becoming a B Corporation by 2025.

SOURCE Prickly Paws

Related links

https://zestypaws.com


Source link

Big Data Pharmaceutical Advertising Market 2021 Outlook, Demand, Regional Analysis, Industry Value Chain

0

Reports Globe’s new report on Global Big Data Pharmaceutical Advertising Market provides in-depth coverage of industry and important market trends with historical and forecast market information, demand, application insights, price trends and shares from leading pharmaceutical advertising company Big Data by geography. This report also studies the Big Data Pharmaceutical Advertising market share, competitive landscape, market share, growth rate, future trends, marketers, opportunities and challenges, sales channels and distributors. . The report divides the market size, by volume and value, based on application, type, and geography.

The Global Big Data Pharmaceutical Advertising Market 2021 report covers endless knowledge and insights into market definition, rankings, applications, and engagement and explains the market drivers and limitations of SWOT analysis. By applying business insights in this Big Data Pharmaceutical Advertising industry report, industry experts measure strategic options, summarize successful action plans, and help businesses make critical bottom line decisions.

Get a FREE copy of this report with charts and graphs at: https://reportsglobe.com/download-sample/?rid=339419

The segmentation chapters allow the readers to understand aspects of the market such as its products, available technology, and applications. These chapters are written to describe their development over the years and the course they are likely to take in the years to come. The research report also provides detailed information on new trends that could define the development of these segments in the coming years.

Segmentation of the Big Data pharmaceutical advertising market:

Big Data Pharmaceutical Advertising Market, By Application (2016-2027)

  • Targeting of products and services
  • Customer targeting
  • Branding

Big Data Pharmaceutical Advertising Market, By Product (2016-2027)

  • Product website and e-commerce
  • Social media
  • Search engine
  • Mobile Ads

Main players operating in the Big Data pharmaceutical advertising market:

  • International Business Machines Corporation
  • Oracle
  • Tata Consultancy Services Limited
  • Statistical analysis system
  • TAKE Solutions Ltd

Company Profiles – This is a very important section of the report which contains accurate and detailed profiles for the major players in the global Big Data Pharmaceutical Advertising Market. It provides information on core business, markets, gross margin, revenue, price, production, and other factors that define the market development of the players studied in the Big Data Pharmaceutical Advertising Market report.

Global Big Data Pharmaceutical Advertising Market: Regional Segments

The various sections on regional segmentation present regional aspects of the Global Big Data Pharmaceutical Advertising Market. This chapter describes the regulatory structure likely to have an impact on the entire market. It highlights the political landscape of the market and predicts its influence on the global Big Data pharmaceutical advertising market.

  • North America (United States, Canada)
  • Europe (Germany, United Kingdom, France, rest of Europe)
  • Asia Pacific (China, Japan, India, rest of Asia-Pacific)
  • Latin America (Brazil, Mexico)
  • Middle East and Africa

Get up to 50% off this report at: https://reportsglobe.com/ask-for-discount/?rid=339419

The objectives of the study are:

  1. To analyze the global Big Data Pharmaceutical Advertising status, future forecast, growth opportunities, key market and major players.
  2. – Present the development of Big Data pharmaceutical advertising in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
  3. Draw up a strategic profile of the main players and analyze in depth their development plan and strategies.
  4. To define, describe, and forecast the market by product type, market applications, and key regions.

This report includes the market size estimate for Value (Million USD) and Volume (K units). Top-down and bottom-up approaches have been used to estimate and validate the market size of the Big Data Pharmaceutical Advertising market, to estimate the size of various other dependent submarkets in the overall market. Major market players were identified by secondary research, and their market shares were determined by primary and secondary research. All percentages, divisions and distributions were determined using secondary sources and verified primary sources.

Some important points from the table of contents:

Chapter 1. Research methodology and data sources

Chapter 2. Executive summary

Chapter 3. Big Data Pharmaceutical Advertising Market: Industry Analysis

Chapter 4. Big Data Pharmaceutical Advertising Market: Product Overview

Chapter 5. Big Data Pharmaceutical Advertising Market: Application Information

Chapter 6. Big Data Pharmaceutical Advertising Market: Regional Insights

Chapter 7. Big Data Pharmaceutical Advertising Market: Competitive Landscape

Ask your questions about personalization to: https://reportsglobe.com/need-customization/?rid=339419

How Reports Globe is different from other market research providers:

The creation of Reports Globe was supported by providing clients with a holistic view of market conditions and future possibilities / opportunities to derive maximum profit from their businesses and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and come up with the best possible solutions to meet your research needs.

Our Reports Globe team follows a rigorous data validation process, which allows us to publish editor reports with minimal or no deviation. Reports Globe collects, separates and publishes more than 500 reports per year covering products and services in many fields.

Contact us:

Mr. Mark Willams

Account Manager

United States: + 1-970-672-0390

E-mail: [email protected]

Website: Reportsglobe.com


Source link

Pharmaceutical Packaging Machinery Market 2021: Global Industry Size and Growth Opportunities Till 2027

0

Reports Globe’s new report on Global Pharmaceutical Packaging Machinery Market offers in-depth coverage of industry and significant market trends with historical and forecast market information, demand, application information, price trends and shares of the leading packaging machinery company pharmaceuticals by geography. This report also studies the Pharmaceutical Packaging Machines market share, competitive landscape, market share, growth rate, future trends, marketers, opportunities and challenges, sales channels and marketers. distributors. The report divides the market size, by volume and value, based on application, type, and geography.

The Global Pharmaceutical Packaging Machinery Market 2021 report covers endless knowledge and insights into the market definition, rankings, applications and engagement and explains the market drivers and limitations of the SWOT analysis. Applying business insights in this Pharmaceutical Packaging Machinery industry report, industry experts measure strategic options, summarize successful action plans, and help companies make critical bottom line decisions.

Get a FREE copy of this report with charts and graphs at: https://reportsglobe.com/download-sample/?rid=329902

The segmentation chapters allow the readers to understand aspects of the market such as its products, available technology, and applications. These chapters are written to describe their development over the years and the course they are likely to take in the years to come. The research report also provides detailed information on new trends that could define the development of these segments in the coming years.

Pharmaceutical packaging machinery market segmentation:

Pharmaceutical Packaging Machinery Market, By Application (2016-2027)

  • Solid pharmaceutical packaging
  • Semi-solid packaging
  • Liquid pharmaceutical packaging
  • Others

Pharmaceutical Packaging Machinery Market, By Product (2016-2027)

Major Players Operating in the Pharmaceutical Packaging Machinery Market:

  • IMA SpA
  • Robert Bosch GmbH
  • Bausch & Strobel Maschinenfabrik Ilshofen
  • Bradman Lake Group
  • Korber
  • Loveshaw Corp
  • Spa of the Marchesini group
  • Mg2
  • Multivac Group
  • Norden Machinery AB
  • Optima packing group
  • Romaco Pharmatechnik
  • Tetra Laval International SA
  • Uhlmann Group and Winpak Ltd

Company Profiles – This is a very important section of the report which contains accurate and detailed profiles for the major players in the global Pharmaceutical Packaging Machinery Market. It provides information on core business, markets, gross margin, revenue, price, production, and other factors that define the market development of the players studied in the Pharmaceutical Packaging Machines Market report.

Global Pharmaceutical Packaging Machinery Market: Regional Segments

The various sections on regional segmentation give regional aspects of the global Pharmaceutical Packaging Machines Market. This chapter describes the regulatory structure likely to have an impact on the entire market. It highlights the political landscape of the market and predicts its influence on the global pharmaceutical packaging machinery market.

  • North America (United States, Canada)
  • Europe (Germany, United Kingdom, France, rest of Europe)
  • Asia Pacific (China, Japan, India, rest of Asia-Pacific)
  • Latin America (Brazil, Mexico)
  • Middle East and Africa

Get up to 50% off this report at: https://reportsglobe.com/ask-for-discount/?rid=329902

The objectives of the study are:

  1. To analyze the global Pharmaceutical Packaging Machinery status, future forecast, growth opportunities, key market and major players.
  2. To present the development of Pharmaceutical Packaging Machines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
  3. Draw up a strategic profile of the main players and analyze in depth their development plan and strategies.
  4. To define, describe, and forecast the market by product type, market applications, and key regions.

This report includes the market size estimate for Value (Million USD) and Volume (K units). Top-down and bottom-up approaches have been used to estimate and validate the market size of the Pharmaceutical Packaging Machines market, to estimate the size of various other dependent submarkets in the overall market. Major market players were identified by secondary research, and their market shares were determined by primary and secondary research. All percentages, divisions and distributions were determined using secondary sources and verified primary sources.

Some important points from the table of contents:

Chapter 1. Research methodology and data sources

Chapter 2. Executive summary

Chapter 3. Pharmaceutical Packaging Machinery Market: Industry Analysis

Chapter 4. Pharmaceutical Packaging Machinery Market: Product Overview

Chapter 5. Pharmaceutical Packaging Machinery Market: Application Information

Chapter 6. Pharmaceutical Packaging Machinery Market: Regional Insights

Chapter 7. Pharmaceutical Packaging Machinery Market: Competitive Landscape

Ask your questions about personalization to: https://reportsglobe.com/need-customization/?rid=329902

How Reports Globe is different from other market research providers:

The creation of Reports Globe was supported by providing clients with a holistic view of market conditions and future possibilities / opportunities to derive maximum profit from their businesses and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and come up with the best possible solutions to meet your research needs.

Our Reports Globe team follows a rigorous data validation process, which allows us to publish editor reports with minimal or no deviation. Reports Globe collects, separates and publishes more than 500 reports per year covering products and services in many fields.

Contact us:

Mr. Mark Willams

Account Manager

United States: + 1-970-672-0390

E-mail: [email protected]

Website: Reportsglobe.com


Source link

Cordyceps Supplements Market with in-depth industry analysis report on trends, growth, opportunities, and forecast till 2026

0

The business intelligence report OnCordyceps Supplements Market enables businesses and other stakeholders to enhance their revenue generation potential by effectively addressing current and future challenges in this vertical. It also encompasses all other crucial metrics such as key trends, driving forces, and lucrative prospects that impact the dynamics of the industry.

Moreover, the document sheds light on the factors contributing to the development of each market segment, while simultaneously revealing key revenue prospects. Moreover, it compares the past and current business scenario to offer a better understanding of the behavior of the market and submarkets during the forecast period.

Going forward, the report assesses the competitive landscape, uncovering the positioning of key competitors, emerging players, and new entrants in the industry. In addition, it examines the consequences of COVID-19 to accurately predict the growth trajectory of this vertical for years to come.

Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/3189

Key Points From Table Of Contents Of Cordyceps Supplements Market Report:

Product landscape

  • Product line: Capsules, Tablets and Others
  • Total compensation and market share of each product segment
  • Estimate of the growth rate of each type of product over the forecast period

Scope

  • Application spectrum: Hospital, Pharmacy, Other,, By region, North America, United States, Canada, Europe, Germany, France, United Kingdom, Italy, Russia, Asia-Pacific, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Latin America, Mexico, Brazil, Argentina, Middle East & Africa, Turkey, Saudi Arabia, United Arab Emirates, By business, Mushroom Science, Host Defense, Paradise Herbs, Oregon’s Wild Harvest, Perfect Supplements LLC, Real Herbs, Aloha Medicinals, Solaray, and Pure Essence Labs
  • Product demand and industry share of each application segment
  • Growth rate of each application segment over the analysis period

Geographical scope

  • Regional bifurcation: North America, Europe, China, Japan, Southeast Asia, India and other regions.
  • Overall revenues raised and sales generated by each regional market
  • Regional market growth rate estimates over the evaluation period

Competition arena

  • Major industry players: Mushroom Science Host Defense Paradise Herbs Oregon’s Wild Harvest Perfect Supplements LLC Real Herbs Aloha Medicinals Solaray Pure Essence Labs
  • Calculation of the market concentration ratio
  • Comprehensive information on the top companies including their business profiles, product portfolios and manufacturing units in the regions served
  • Statistics regarding sales, market share, pricing model and other financial parameters of the companies mentioned
  • Records of recent acquisitions, mergers and expansion tactics

In summary, the research literature involves a complete inspection of the Cordyceps Supplement market by examining various segments of the industry. In addition, it informs the industry supply chain, identifying the distribution channel, downstream consumers and upstream suppliers, to guide companies in effectively marketing their products and services.

Some of the key questions this report answered:

What will the market growth rate, growth dynamics or market acceleration be during the forecast period?

What are the key factors driving the Cordyceps Supplement market?

What was the size of the emerging Cordyceps supplements market in value in 2020?

What will be the size of the emerging Cordyceps supplements market in 2026?

Which region is expected to hold the highest market share in the Cordyceps Supplement Market?

What trends, challenges, and obstacles will impact the development and size of the global Cordyceps Supplements market?

What are the sales volume, revenue, and price analysis of the major manufacturers of the Cordyceps Supplements market?

Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/3189


Source link

Flora growth stocks rose 43.93%: why it happened

0

  • The shares of Flora Growth Corp. (NASDAQ: FLGC) rose 43.93%. That’s why it happened.

The shares of Flora Growth Corp. (NASDAQ: FLGC) – an all-outdoor grower and maker of cannabis-derived products and brands – rose 43.93% from a previous close of $ 8.81 to $ 12.68. Investors appear to be responding positively to the Company’s release of certain financial and operating results for the 6-month period ending June 30, 2021.

Financial summary for the first semester:

– Flora Growth generated revenues of + $ 2M with a gross margin of 60% (unaudited), compared to revenues of ~ $ 100K for 2020.

– Operating expenses for the first half of the year amounted to $ 6 million, for a net loss of $ 4 million (unaudited). However, these results were strongly affected by nearly $ 3M of one-time IPO-related expenses (unaudited).

– As of June 30, 2021, Flora’s cash balance was approximately $ 19 million with minimal debt (unaudited).

– After June 30, the company has recorded substantial cash inflows from the exercise of warrants sold under Settlement A. And to date the company has received commitments of over $ 10 million (some unfunded), with $ 7.2 million in cash received and an additional $ 1 million pending clearing. Flora expects this amount to continue to increase over the following weeks.

Second Quarter 2021 Operational Highlights:

– Completion of a successful IPO and public listing on the Nasdaq Capital Market under the ticker symbol “FLGC”; Flora is the first known outdoor grower ever to be listed on NASDAQ, the first cannabis company to be listed via a traditional IPO on a U.S. stock exchange, and has what management believes is the largest licensed cultivation footprint in Colombia. .

– Announcement of the intention to purchase 100% of Koch & Gsell, manufacturer of the leading Swiss brand of hemp and tobacco pre-roll Heimat

– The company made a strategic investment of $ 2.4 million in Hoshi International, opening the distribution of Flora’s product portfolio in the European Union (EU)

– Expansion into UK and Central American markets with sales to new international distribution partners; bringing to 13 the total number of countries in which Flora and its divisions currently have a product on the market

– Formation of the Flora Lab manufacturing division which operates a modern 16,000 square foot manufacturing facility and holds multiple GMP certifications with a diverse portfolio comprising over 190 products and 63 over-the-counter (OTC) products registered and licensed by INVIMA ( FDA equivalent in Colombia).

Operational highlights after period end:

– Kasa Wholefoods., The food division of Flora, has signed a sales agreement to supply food products to Colombia’s largest consumer packaged goods (CPG) distributor, Tropi, which has more than 130,000 distribution points in 38 cities in Colombia; Kasa has since completed its first purchase order valued at around $ 1.1 million and expects this initial deal to generate additional revenue from its CBD and hemp portfolio, expecting future sales. reach about $ 2 million per month.

– Announced intention to purchase 100% of Vessel Brand, an industry leader in luxury cannabis consumption technology

– Announcement of intention to form a joint venture with Avaria, a Canadian company, the manufacturer and owner of KaLaya, an award-winning pain relief cream distributed across Canada

– Following the reform of Colombian cannabis legislation aimed at improving access to cannabis products for Colombians and positioning Colombia as a leader for the supply of the global cannabis market, Flora immediately announced that it had signed a letter of intent with Kiricann, an international distributor with operations in South Africa and distribution agreements in Germany and the EU, to supply its dried flowers and derivatives; In addition, the company announced plans for the manufacture, sale and distribution of CBD infused food and drink products; further plans to increase awareness of its premium brand and product portfolio due to relaxed marketing restrictions; and, finally, plans to manufacture tailor-made cannabis-based pharmaceuticals for the Colombian medical cannabis market

– Announcement of the intention of Evergreen Pharmacare, an authorized Australian importer and distributor of medical cannabis products, to supply its high-end dried flowers and derivative products to the Australian medical cannabis and over-the-counter CBD markets

– The Flora Beauty division officially launched Ô (“Awe”), its premium brand and product line designed and marketed by founding partner, trendsetter and global beauty influencer Paulina Vega

– Announced that after performing a thorough and meticulous review, it plans to move its headquarters to Miami, Florida by Q1 2022

– Continued expansion of its scientific and academic activities with the appointment of another advisor and key partnership:

– Engagement of Brigitte Baptiste as strategic advisor and conclusion of a cooperation agreement with EAN University

KEY QUOTE:

“The first half of our fiscal year is marked by a number of extraordinary accomplishments from our team despite the challenges of the global pandemic. Management believes that each of our divisions has gained ground from where we started the year as we execute the strategic growth plan we set out in December 2020, positioning shareholders for future success. By the end of last year, Flora was private, largely pre-recipe, and focused primarily on Latin America; Over the past six months, Flora has completed its IPO on NASDAQ, while increasing its global distribution, revenue, and expanding its high-end portfolio of global cannabis brands and products. We have made a number of strategic hires and appointments to build a strong and highly experienced management team, while simultaneously leveraging our capital on an attractive risk-adjusted basis. We announced our intention to make several strategic investments and acquisitions, entered into several international sales agreements for our cannabis flower and its derivatives, and significantly expanded distribution and sales with our downstream premium cannabis brands and products in the pharmaceutical fields. , natural wellness, cosmetics, food and drink and hemp textile segments. Going forward, we are excited about the strategic opportunities for incremental growth as we seek to leverage our globally recognized house of brands and products into new markets and categories around the world, particularly in the Americas, in the EU and Australia. In conclusion, the board of directors, management and staff of Flora would like to thank our shareholders who trust us to increase their investment and generate substantial value. We do not take this lightly and strongly believe in a strong corporate governance regime, providing full transparency regarding our efforts and activities as we continue to move forward to become the global supplier of CPG cannabis brands and products. high-end while driving revenue responsibly and strategically. growth.”

– Luis Merchan, President and CEO of Flora

Disclaimer: This content is intended for informational purposes. Before you make an investment, you need to do your own analysis.


Source link

Atrophic Gastritis Treatment Market Research Report 2021 Cumulative Impact of COVID-19 | Takeda Pharmaceutical Company Limited, PERNIX Therapeutics, Perrigo Pharmaceutical

0

A2Z Market Research announces the release of Atrophic Gastritis Treatment Market research report. The market is expected to grow at a sustained rate in the coming years. The 2021 Atrophic Gastritis Treatment Market Research Report presents an analysis of the market size, share and growth, trends, cost structure, statistical and comprehensive data of the global market. The report gives a clear picture of the current market situation. It includes the digital wallpaper of historical and technological advent, macroeconomic and driving factors and assesses the market size in terms of value and volume, in the market.

Get a sample report with the latest analysis of industry trends:

https://www.a2zmarketresearch.com/sample?reportId=87424

Major companies in this report are: Takeda Pharmaceutical Company Limited, PERNIX Therapeutics, Perrigo Pharmaceutical, Teva Pharmaceutical.

As analytics has become an inherent part of every business activity and role, a central role in the decision-making process of businesses today is mentioned in this report. Over the next few years, the demand for the market is expected to increase dramatically globally, enabling healthy growth of the Atrophic Gastritis Treatment market is also detailed in the report. This report highlights the manufacturing cost structure which includes cost of materials, cost of labor, depreciation cost, and cost of manufacturing procedures. Price analysis and equipment supplier analysis is also performed by analysts in the report.

This research report represents a 360-degree overview of the competitive landscape of the Employee Protection Software Market. In addition, it offers massive data relating to recent trends, technological advancements, tools and methodologies. The research report analyzes the Employee Protection Software market in a detailed and concise manner for a better understanding of businesses.

The report, using detailed business profiles, project feasibility analysis, SWOT review, and some different insights of key organizations working in the Atrophic Gastritis Treatment market, presents a scientific record point by point of the competitive market scenario. The report also presents a review of the effect of recent market developments on the future development prospects of the market.

Market segmentation

Segment by type

Coating Agents, Antibiotics, Vitamin B-12

Segment by application

Hospital pharmacies, retail pharmacies, pharmacies, online pharmacies

Get the personalization on this report:

https://www.a2zmarketresearch.com/enquiry?reportId=87424

Geographic analysis

The global atrophic gastritis treatment market is spread across North America, Europe, Asia-Pacific, Middle East and Africa as well as the rest of the world.

COVID-19 impact assessment

The COVID-19 pandemic has emerged in containment across regions, line limitations and the breakdown of transport organizations. In addition, the financial vulnerability of the atrophic gastritis treatment market is much higher than past outbreaks such as extreme intense respiratory state (SARS), avian flu, swine flu, avian flu and Ebola, inferred from the increasing number of infected individuals and vulnerability on the end of the crisis. With the rapid increase in cases, the global market for refreshments for the treatment of atrophic gastritis is influenced from several points of view.

Accessibility of the workforce is obviously disrupting the inventory network of the global beverage market for the treatment of atrophic gastritis, as the lockdown and spread of the infection causes individuals to stay on the market. interior. The presentation of the manufacturers of atrophic gastritis treatment and the transport of the products are associated. If the assembly movement is stopped, the transport as well as the warehouse network also stop. Stacking and dumping of items i.e. raw materials and results (fasteners), which requires a ton of labor, is also heavily affected due to the pandemic. From the entrance of the assembly plant to the warehouse or distribution center to end customers, i.e. application companies, the entire gastritis treatment inventory network atrophic is severely compromised because of the episode.

The research provides answers to the following key questions:

  • What is the projected size of the Atrophic Gastritis Treatment market by 2027?
  • What will the normal share of the industry as a whole be for the years to come?
  • What are the significant components and restraints in the development of the global Atrophic Gastritis Treatment market across varying geographies?
  • Who are the major sellers expected to dominate the market for the 2021 to 2027 evaluation period?
  • What are the moving and upcoming advancements expected to influence the advancement of the global Atrophic Gastritis Treatment market?
  • What are the development techniques received by major market sellers to stay ahead of the curve?

Buy an exclusive report:

https://www.a2zmarketresearch.com/buy?reportId=87424

Contact us:

Roger smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[email protected]

+1 775 237 4147

Global Poultry Health Market Report 2021 Size, Share, Growth and Forecast to 2028


Source link

Pharmaceutical Sterility Testing Market to Experience Strong Expansion by 2027 | SGS SA, Toxikon, Inc.

0

A2Z Market Research announces the release of Pharmaceutical Sterility Testing Market research report. The market is expected to grow at a sustained rate in the coming years. The 2021 Pharmaceutical Sterility Testing Market research report presents an analysis of the market size, share and growth, trends, cost structure, statistical and comprehensive data of the global market. The report gives a clear picture of the current market situation. It includes the digital wallpaper of historical and technological advent, macroeconomic and driving factors and assesses the market size in terms of value and volume, in the market.

Get a sample report with the latest analysis of industry trends:

https://www.a2zmarketresearch.com/sample?reportId=87397

Key Companies in this Report are: SGS SA, Toxikon, Inc., Pace Analytical Services, LLC, Boston Analytical, Charles River Laboratories International, Inc., Nelson Laboratories ..

As analytics has become an inherent part of every business activity and role, a central role in the decision-making process of businesses today is mentioned in this report. Over the next few years, the demand for the market is expected to increase dramatically globally, enabling healthy growth of the Pharmaceutical Sterility Testing market is also detailed in the report. This report highlights the manufacturing cost structure which includes cost of materials, cost of labor, depreciation cost, and cost of manufacturing procedures. Price analysis and equipment supplier analysis is also performed by analysts in the report.

This research report represents a 360-degree overview of the competitive landscape of the Employee Protection Software Market. In addition, it offers massive data relating to recent trends, technological advancements, tools and methodologies. The research report analyzes the Employee Protection Software market in a detailed and concise manner for a better understanding of businesses.

The report, with the help of detailed business profiles, project feasibility analysis, SWOT review, and some different insights of key organizations working in the Pharmaceutical Sterility Testing market, presents a scientific record point by point of the competitive market scenario. The report also presents a review of the effect of recent market developments on the future development prospects of the market.

Market segmentation

Segment by type

Sterility tests, bioburden tests, bacterial endotoxin tests

Segment by application

Preparation pharmacies, medical device companies, pharmaceutical companies, others

Get the personalization on this report:

https://www.a2zmarketresearch.com/enquiry?reportId=87397

Geographic analysis

The global pharmaceutical sterility testing market is spread across North America, Europe, Asia-Pacific, Middle East & Africa as well as the rest of the world.

COVID-19 impact assessment

The COVID-19 pandemic has emerged in containment across regions, line limitations and the breakdown of transport organizations. In addition, the financial vulnerability of the pharmaceutical sterility testing market is much higher than past outbreaks such as extreme intense respiratory disease (SARS), avian flu, swine flu, avian flu and Ebola, inferred from the growing number. of infected people and vulnerability on the end of the crisis. With the rapid increase in cases, the global pharmaceutical sterility testing refreshments market is influenced from several perspectives.

Accessibility of workforce is disrupting the global pharmaceutical sterility testing drink market inventory network in every way, as lockdown and spread of infection causes individuals to stay indoors. The presentation of manufacturers of pharmaceutical sterility tests and the transport of products are associated. If the assembly movement is stopped, the transport as well as the warehouse network also stop. Stacking and dumping of items i.e. raw materials and results (fasteners), which requires a ton of labor, is also heavily affected due to the pandemic. From the entrance of the assembly plant to the warehouse or distribution center to end customers, i.e. application companies, the entire pharmaceutical sterility testing inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

  • What is the projected market size of the pharmaceutical sterility testing market by 2027?
  • What will the normal share of the industry as a whole be for the years to come?
  • What is the significant development of the components and restraints of the global pharmaceutical sterility testing market in different geographies?
  • Who are the major sellers expected to dominate the market for the 2021 to 2027 evaluation period?
  • What are the moving and upcoming advancements expected to influence the advancement of the global Pharmaceutical Sterility Testing market?
  • What are the development techniques received by major market sellers to stay ahead of the curve?

Buy an exclusive report:

https://www.a2zmarketresearch.com/buy?reportId=87397

Contact us:

Roger smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[email protected]

+1 775 237 4147

Global Automotive Fog Lights Market Report 2021 Size, Share, Growth and Forecast to 2028


Source link

Pharmaceutical Contract Manufacturing and Contractual Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth

0

Reports Globe’s new report on Global Pharmaceutical contract manufacturing and contract market offers in-depth coverage of industry and important market trends with historical and forecast market information, demand, application information, price trends and shares of the leading manufacturing and contracts company pharmaceuticals by geographic area. This report also studies the Pharmaceuticals and Contract Manufacturing market share, competitive landscape, market share, growth rate, future trends, marketers, opportunities and challenges, sales channels. and distributors. The report divides the market size, by volume and value, based on application, type, and geography.

The Global Pharmaceutical Contract Manufacturing & Contract Market 2021 report covers endless knowledge and insights into the market definition, rankings, applications and engagement and explains the market drivers and limitations of the SWOT analysis. By applying business insights in this pharmaceutical manufacturing and contracting industry report, industry experts measure strategic options, summarize successful action plans, and help companies make critical decisions about results.

Get a FREE copy of this report with charts and graphs at: https://reportsglobe.com/download-sample/?rid=304830

The segmentation chapters allow the readers to understand aspects of the market such as its products, available technology, and applications. These chapters are written to describe their development over the years and the course they are likely to take in the years to come. The research report also provides detailed information on new trends that could define the development of these segments in the coming years.

Segmentation of the pharmaceutical contract manufacturing market and contracts:

Pharmaceutical Manufacturing and Contracting Market, By Application (2016-2027)

  • Small Medium Business
  • Big business

Pharmaceutical Manufacturing and Contracting Market, by Product (2016-2027)

Main players operating in the pharmaceutical manufacturing and manufacturing contract market:

  • Catalent
  • Pharmaceutical Product Development LLC
  • AbbVie
  • Baxter BioPharma Solutions
  • Pathéon
  • Grifols International
  • Dalton Pharmaceutical Services
  • Boehringer Ingelheim Biopharmaceuticals GmBh
  • Lonza AG.
  • Grifols SA
  • Jubilant Life Sciences Limited
  • QuintilesIMS
  • Vetter Pharma
  • Ligand Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International Inc.
  • Recipharm AB
  • Famar Health Care Services
  • Western Pharmaceutical Services, Inc.

Company Profiles – This is a very important section of the report which contains accurate and detailed profiles for the major players in the global pharmaceutical manufacturing and contracts market. It provides information on core business, markets, gross margin, revenue, price, production, and other factors defining the market development of the players studied in the Manufacturing and Contracts Market report. pharmaceuticals.

Global Contract Manufacturing and Pharmaceutical Contract Manufacturing Market: Regional Segments

The various sections on regional segmentation present regional aspects of the global pharmaceutical manufacturing and contracts market. This chapter describes the regulatory structure likely to have an impact on the entire market. It highlights the political landscape of the market and predicts its influence on the global pharmaceutical manufacturing and manufacturing contract market.

  • North America (United States, Canada)
  • Europe (Germany, United Kingdom, France, rest of Europe)
  • Asia Pacific (China, Japan, India, rest of Asia-Pacific)
  • Latin America (Brazil, Mexico)
  • Middle East and Africa

Get up to 50% off this report at: https://reportsglobe.com/ask-for-discount/?rid=304830

The objectives of the study are:

  1. To analyze the global pharmaceutical manufacturing and contracts status, future forecast, growth opportunities, key market and major players.
  2. To present the development of pharmaceutical manufacturing and manufacturing contract in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
  3. Draw up a strategic profile of the main players and analyze in depth their development plan and strategies.
  4. To define, describe, and forecast the market by product type, market applications, and key regions.

This report includes the market size estimate for Value (Million USD) and Volume (K units). Top-down and bottom-up approaches have been used to estimate and validate the market size of the Pharmaceutical Contract Manufacturing and Manufacturing market, to estimate the size of various other dependent submarkets in the overall market. Major market players were identified by secondary research, and their market shares were determined by primary and secondary research. All percentages, divisions and distributions were determined using secondary sources and verified primary sources.

Some important points from the table of contents:

Chapter 1. Research methodology and data sources

Chapter 2. Executive summary

Chapter 3. Pharmaceutical Manufacturing and Contracts Market: Industry Analysis

Chapter 4. Pharmaceutical Contract Manufacturing and Contract Market: Product Overview

Chapter 5. Pharmaceutical Manufacturing and Manufacturing Contracts Market: Application Information

Chapter 6. Pharmaceutical Manufacturing Contract and Manufacturing Market: Regional Insights

Chapter 7. Pharmaceutical Contract Manufacturing and Contract Market: Competitive Landscape

Ask your questions about personalization to: https://reportsglobe.com/need-customization/?rid=304830

How Reports Globe is different from other market research providers:

The creation of Reports Globe was supported by providing clients with a holistic view of market conditions and future possibilities / opportunities to derive maximum profit from their businesses and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and come up with the best possible solutions to meet your research needs.

Our Reports Globe team follows a rigorous data validation process, which allows us to publish editor reports with minimal or no deviation. Reports Globe collects, separates and publishes more than 500 reports per year covering products and services in many fields.

Contact us:

Mr. Mark Willams

Account Manager

United States: + 1-970-672-0390

E-mail: [email protected]

Website: Reportsglobe.com


Source link

COOPER PHARMA and OSI sign distribution agreement to protect and prevent against respiratory viruses, including the one that causes COVID-19

0

BROSSARD, QC and Casablanca, Morocco, August 11, 2021 / CNW / – An innovative broad-spectrum natural organic barrier is needed to prevent viral respiratory infections. COOPER PHARMA and OSI have signed a distribution agreement to market Flavobac ™ Cold & Flu Guard ™. Under the terms of this agreement, OSI grants COOPER PHARMA the exclusive right to distribute Flavobac ™ Cold & Flu Guard ™ in Morocco and the United Arab Emirates (UNITED ARAB EMIRATES). COOPER PHARMA and its affiliates will use their sales, marketing and e-commerce expertise to distribute Flavobac ™ Cold & Flu Guard ™ once product registration has been obtained from Moroccan and UAE health authorities.

Flavobac ™ Cold & Flu Guard ™ will become an essential part of COOPER PHARMA’s medical solutions, to protect children, parents, healthcare professionals and society against respiratory viruses including SARS-CoV-2 which causes COVID- 19. “COOPER PHARMA is committed to helping reduce the impact of respiratory viral infections” declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA.

Christian Sauvageau, President of OSI, said: “We are extremely proud of this opportunity to work with such a forward-thinking company as COOPER PHARMA. We have seen COOPER PHARMA’s total determination to bring innovative solutions to market and we are delighted to work with them. We also thank The Harel Group for identifying COOPER PHARMA as a strategic partner and for facilitating the entire transaction process, from the introduction to the execution of final agreements with COOPER PHARMA. “

Flavobac ™ Cold & Flu Guard ™ is a formulation based on a substance obtained from a natural source. It fights viruses by interfering with their ability to adhere to the oral and nasal mucosa. Flavobac ™ Cold & Flu Guard ™ has been shown to kill “99.8% of SARS-CoV-2 within 5 minutes as well as many other respiratory viruses such as human coronavirus, influenza virus, rhinovirus and VRS1. Flavobac ™ Cold & Flu Guard ™ is already registered in Europe, Canada and the United States. Efforts are underway to enable its use around the world. For more information, see www.coldandfluguard.com

“COOPER PHARMA is proud to receive the distribution rights of Flavobac ™ Cold & Flu Guard ™ from our partner OSI in order to help people and healthcare professionals to protect themselves against respiratory viral infections, while respecting of course and above all the health recommendations in terms of prevention and treatment against respiratory viruses and in particular SARS-CoV-2 “declared Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA. “An innovative broad-spectrum barrier to help reduce viral spread and viral loads is an important new option for protecting against respiratory viruses. Flavobac ™ Cold & Flu Guard ™ can neutralize viruses that have entered the nose and mouth and act as “local disinfectants” to destroy viruses before they have a chance to cause infection. Morocco, COOPER PHARMA is happy to provide people with a new tool to protect themselves against respiratory viruses, ”said Ayman Cheikh-Lahlou.

About COOPER PHARMA
Since 1933, Cooper Pharma, a Moroccan pharmaceutical company, has supported health professionals in the service of a mission: to increase access to medicines for all. Cooper Pharma is today a leading laboratory in the national pharmaceutical industry, with its range of Cooper products, covering more than a hundred specialties and major therapeutic areas. Alongside its own products, Cooper Pharma is the partner of around twenty multinationals for which it represents around a hundred drugs, under license. Cooper Pharma is a producer, distributor and exporter of pharmaceutical specialties. Cooper Pharma is today a benchmark player in the Africa and Middle East region with commercial reach in Europe. Cooper Pharma has nine pharmaceutical factories that are wholly owned or in JV with local leaders on North Africa, West Africa, East Africa, the Gulf Cooperation Council countries and Europe. For more information, please visit: https://cooperpharma.ma/en/

About OSI
Oral Science International (OSI) is an innovation-driven company dedicated to the development and commercialization of innovative biotechnologies, providing solutions to oral / nasal infections and inflammation. Oral Science International has a strong and passionate management team committed to innovative oral care and infection control technologies that improve the quality of life for people of all ages. We are committed to customer-centric design and science-driven innovation. We are focused on providing safe, valuable and easy to use products for the global market. Our commitment to innovation, partnership and excellence rests on the foundation of a culture that greatly values ​​collaboration. We are guided by in-depth research that we share through publications and presentations, and in collaboration with all stakeholders. www.oralscience.com

About the Harel group
The Harel Group is a business development consultancy with in-depth industry knowledge and an extensive network of contacts in the pharmaceutical, biotechnology, diagnostics and medical devices sectors. The Harel Group supports clients looking to expand their global business footprint by identifying strategic partners and facilitating licensing and distribution agreements. For more information, please visit: https://www.theharelgroup.com/

  • Efficacy of the bioflavonoid spray against respiratory viruses, Z Cheikh, H Lerner, Oral health, July 9, 2021
  • SOURCE Oral Science International


    Source link

    Vallon Pharmaceuticals will present at Q3 Virtual

    0

    Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18e 12:30 PM HEY

    PHILADELPHIA, PA, Aug 11, 2021 (GLOBE NEWSWIRE) – Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs designed to deter abuse in the treatment of the central nervous system (CNS ), today announced that David Baker, President and CEO of Vallon, will be presenting at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 p.m. ET.

    In addition to the presentation, management will be available to participate in one-on-one virtual meetings with qualified members of the investment community who have registered to attend the conference. For more information on the conference, please visit the conference website.

    A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.

    About Vallon Medications, Inc.

    Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania. The Company is focused on the development of new drugs to help patients with central nervous system (CNS) disorders. The Company’s lead product candidate, ADAIR, is a novel immediate-release amphetamine abuse deterrent formulation under development for the treatment of ADHD and narcolepsy.

    For more information about the company, please visit www.vallon-pharma.com or contact us on LinkedIn or Twitter.

    References and links to websites have been provided as a convenience, and the information contained on such website does not form part of, or by reference to, this press release. Vallon is not responsible for the content of third party websites.

    Investor Contact:
    JTC Team, LLC
    Jenene thomas
    (833) 475-8247
    vallon@jtcir.com


    Source link